Our data would suggest that application of putative PHLPP2 agonists or liver-specific delivery of non-specific PHLPP activators52 have the potential to stem the tide of obesity-induced NAFLD. Here, PHLPP1 is linked to obesity due to melanocortin 4 receptor deficiency.